Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 3Breast Neoplasms 3Papillomavirus Infections 2Melanoma 2Lung Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Sarcoma 1Prostatic Neoplasms 1Neuroblastoma 1Neoplasms, Nerve Tissue 1NY-ESO-1-expressing Tumors 1Leukemia, Myeloid, Acute 1Herpes Zoster 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Condylomata Acuminata 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Anus Neoplasms 1Adenoviridae Infections 1Adenocarcinoma 1

Interventions

Papillomavirus Vaccines 2green tea extract polyphenone E 1Vaccines 1Tea 1Injections 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1GS-9191 1Cidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Condylomata Acuminata × Vaccines × Clear all
NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡